ReviewInternational journal of pharmaceutics: X2026
Application of nanozyme-based drug delivery systems in the treatment of ROS-related ophthalmic diseases.
Review in International journal of pharmaceutics: X, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
ROS-related ophthalmic diseases span the ocular surface as well as the anterior and posterior segments of the eye. Dry eye disease (DED), glaucoma, diabetic retinopathy (DR) and age-related macular degeneration (AMD) have distinct anatomical targets but share common pathophysiological features, including oxidative stress, inflammation, vascular dysfunction, epithelial injury or neurodegeneration. Conventional ocular drug delivery and therapeutic modalities are hindered by severe limitations, including low bioavailability in the posterior segment of the eye and the requirement for frequent invasive administration. Nanozymes, an emerging class of therapeutic agents that integrate the properties of nanomaterials with natural enzyme-like catalytic activity, can efficiently scavenge excess reactive oxygen species (ROS) in focal lesions, modulate inflammatory factors, and remodel the pathological microenvironment, thereby providing a novel approach to the treatment of ROS-related ophthalmic diseases. This review systematically elucidates the core characteristics and therapeutic mechanisms of four major categories of nanozymes, namely metal-based, metal oxide-based, carbon-based, and composite nanozymes. To overcome physiological barriers in ocular drug delivery, such as the cornea and the blood-retinal barrier (BRB), we discuss active targeted delivery strategies based on mucin-binding retention, biomimetic cell membrane coating, and molecular ligand-mediated targeting. Furthermore, we summarize the development of intelligent and controlled-release systems in response to specific pathological microenvironments, such as ROS, pH values, and others. Additionally, this review details the latest cutting-edge applications and therapeutic efficacies of nanozymes in specific ophthalmic diseases, including AMD, DR, dry eye disease, and glaucoma. Finally, we highlight the challenges of long-term biosafety evaluation in the bench-to-bedside clinical translation of nanozymes and provide perspectives on future research directions for developing multi-stimuli-responsive synergistic nanodelivery systems.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.